Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of Beraprost. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Beraprost. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Beraprost. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Beraprost is combined with Deferasirox. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Beraprost. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Beraprost. |
| Rivaroxaban | Beraprost may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Beraprost is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Beraprost. |
| Urokinase | Urokinase may increase the anticoagulant activities of Beraprost. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Beraprost. |
| Ursodeoxycholic acid | The risk or severity of adverse effects can be increased when Beraprost is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of adverse effects can be increased when Beraprost is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of adverse effects can be increased when Beraprost is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of adverse effects can be increased when Beraprost is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of adverse effects can be increased when Beraprost is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of adverse effects can be increased when Beraprost is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of adverse effects can be increased when Beraprost is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of adverse effects can be increased when Beraprost is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of adverse effects can be increased when Beraprost is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of adverse effects can be increased when Beraprost is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of adverse effects can be increased when Beraprost is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of adverse effects can be increased when Beraprost is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of adverse effects can be increased when Beraprost is combined with Hyodeoxycholic Acid. |
| Glucosamine | Glucosamine may increase the antiplatelet activities of Beraprost. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Beraprost is combined with Ibritumomab tiuxetan. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Beraprost is combined with Obinutuzumab. |
| Tipranavir | Tipranavir may increase the antiplatelet activities of Beraprost. |
| Vitamin E | Vitamin E may increase the antiplatelet activities of Beraprost. |
| Mifepristone | The serum concentration of Beraprost can be increased when it is combined with Mifepristone. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Beraprost. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with Beraprost. |
| Quinine | The therapeutic efficacy of Beraprost can be increased when used in combination with Quinine. |
| Quinidine | The therapeutic efficacy of Beraprost can be increased when used in combination with Quinidine. |
| Tamoxifen | The risk or severity of bleeding can be increased when Tamoxifen is combined with Beraprost. |
| Toremifene | The risk or severity of bleeding can be increased when Toremifene is combined with Beraprost. |
| Pentoxifylline | The therapeutic efficacy of Beraprost can be increased when used in combination with Pentoxifylline. |
| Pentosan polysulfate | The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Beraprost. |
| Levocarnitine | The therapeutic efficacy of Beraprost can be increased when used in combination with Levocarnitine. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the anticoagulant activities of Beraprost. |
| Chlorotrianisene | Chlorotrianisene may decrease the anticoagulant activities of Beraprost. |
| Conjugated estrogens | Conjugated estrogens may decrease the anticoagulant activities of Beraprost. |
| Mestranol | The risk or severity of adverse effects can be increased when Mestranol is combined with Beraprost. |
| Estrone sulfate | Estrone sulfate may decrease the anticoagulant activities of Beraprost. |
| Quinestrol | Quinestrol may decrease the anticoagulant activities of Beraprost. |
| Hexestrol | Hexestrol may decrease the anticoagulant activities of Beraprost. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Beraprost. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Beraprost. |
| Polyestradiol phosphate | Polyestradiol phosphate may decrease the anticoagulant activities of Beraprost. |
| Esterified estrogens | Esterified estrogens may decrease the anticoagulant activities of Beraprost. |
| Zeranol | Zeranol may decrease the anticoagulant activities of Beraprost. |
| Equol | Equol may decrease the anticoagulant activities of Beraprost. |
| Methallenestril | Methallenestril may decrease the anticoagulant activities of Beraprost. |
| Epimestrol | Epimestrol may decrease the anticoagulant activities of Beraprost. |
| Moxestrol | Moxestrol may decrease the anticoagulant activities of Beraprost. |
| Estradiol acetate | Estradiol acetate may decrease the anticoagulant activities of Beraprost. |
| Estradiol benzoate | Estradiol benzoate may decrease the anticoagulant activities of Beraprost. |
| Estradiol cypionate | Estradiol cypionate may decrease the anticoagulant activities of Beraprost. |
| Estradiol valerate | Estradiol valerate may decrease the anticoagulant activities of Beraprost. |
| Biochanin A | Biochanin A may decrease the anticoagulant activities of Beraprost. |
| Formononetin | Formononetin may decrease the anticoagulant activities of Beraprost. |
| Estriol | Estriol may decrease the anticoagulant activities of Beraprost. |
| Limaprost | The risk or severity of adverse effects can be increased when Limaprost is combined with Beraprost. |
| Icosapent | The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Beraprost. |
| Mesalazine | The risk or severity of bleeding can be increased when Mesalazine is combined with Beraprost. |
| Indomethacin | The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Beraprost. |
| Nabumetone | The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Beraprost. |
| Ketorolac | The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Beraprost. |
| Tenoxicam | The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Beraprost. |
| Celecoxib | The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Beraprost. |
| Tolmetin | The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Beraprost. |
| Rofecoxib | The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Beraprost. |
| Piroxicam | The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Beraprost. |
| Fenoprofen | The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Beraprost. |
| Valdecoxib | The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Beraprost. |
| Diclofenac | The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Beraprost. |
| Sulindac | The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Beraprost. |
| Flurbiprofen | The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Beraprost. |
| Etodolac | The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Beraprost. |
| Mefenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Beraprost. |
| Naproxen | The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Beraprost. |
| Sulfasalazine | The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Beraprost. |
| Phenylbutazone | The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Beraprost. |
| Meloxicam | The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Beraprost. |
| Carprofen | The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Beraprost. |
| Diflunisal | The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Beraprost. |
| Salicylic acid | The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Beraprost. |
| Meclofenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Beraprost. |
| Oxaprozin | The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Beraprost. |
| Ketoprofen | The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Beraprost. |
| Balsalazide | The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Beraprost. |
| Olsalazine | The risk or severity of bleeding can be increased when Olsalazine is combined with Beraprost. |
| Lumiracoxib | The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Beraprost. |
| Magnesium salicylate | The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Beraprost. |
| Salsalate | The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Beraprost. |
| Choline magnesium trisalicylate | The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Beraprost. |
| Antrafenine | The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Beraprost. |
| Aminophenazone | The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Beraprost. |
| Antipyrine | The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Beraprost. |
| Tiaprofenic acid | The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Beraprost. |